TR201100151A2 - Ibandronate formulation. - Google Patents

Ibandronate formulation.

Info

Publication number
TR201100151A2
TR201100151A2 TR2011/00151A TR201100151A TR201100151A2 TR 201100151 A2 TR201100151 A2 TR 201100151A2 TR 2011/00151 A TR2011/00151 A TR 2011/00151A TR 201100151 A TR201100151 A TR 201100151A TR 201100151 A2 TR201100151 A2 TR 201100151A2
Authority
TR
Turkey
Prior art keywords
ibandronate
formulation
ibandronate formulation
prevention
pharmaceutically acceptable
Prior art date
Application number
TR2011/00151A
Other languages
Turkish (tr)
Inventor
Bi̇lgi̇ç Mahmut
Original Assignee
Bi̇lgi̇ç Mahmut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bi̇lgi̇ç Mahmut filed Critical Bi̇lgi̇ç Mahmut
Priority to TR2011/00151A priority Critical patent/TR201100151A2/en
Priority to TR2011/10525A priority patent/TR201110525A2/en
Priority to TR2011/10526A priority patent/TR201110526A2/en
Priority to TR2011/10524A priority patent/TR201110524A2/en
Priority to PCT/TR2012/000008 priority patent/WO2012093977A1/en
Priority to PCT/TR2012/000007 priority patent/WO2012093976A1/en
Priority to PCT/TR2012/000010 priority patent/WO2012093979A1/en
Priority to EP12704937.7A priority patent/EP2661270A1/en
Priority to PCT/TR2012/000006 priority patent/WO2012093975A1/en
Publication of TR201100151A2 publication Critical patent/TR201100151A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Mevcut buluş; kemik erimesi ve ilişkili hastalıkların önlenmesinde ve tedavisinde kullanılmak üzere geliştirilmiş ibandronat ve/veya farmasötik açıdan uygun herhangi bir türevini içeren suda çözünür dozaj formlarını açıklamaktadır.The present invention includes; discloses water-soluble dosage forms containing ibandronate and / or any pharmaceutically acceptable derivative thereof for use in the prevention and treatment of bone resorption and related diseases.

TR2011/00151A 2011-01-06 2011-01-06 Ibandronate formulation. TR201100151A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
TR2011/00151A TR201100151A2 (en) 2011-01-06 2011-01-06 Ibandronate formulation.
TR2011/10525A TR201110525A2 (en) 2011-01-06 2011-10-24 Water-soluble pharmaceutical compositions for use in the treatment of bone diseases.
TR2011/10526A TR201110526A2 (en) 2011-01-06 2011-10-24 Water-soluble pharmaceutical formulations for use in the treatment of bone diseases.
TR2011/10524A TR201110524A2 (en) 2011-01-06 2011-10-24 New water-soluble formulations for use in the treatment of bone diseases.
PCT/TR2012/000008 WO2012093977A1 (en) 2011-01-06 2012-01-03 Water soluble pharmaceutical formulations comprising ibandronate and an inorganic salt for use in treatment of bone diseases
PCT/TR2012/000007 WO2012093976A1 (en) 2011-01-06 2012-01-06 A composition comprising ibandronate at least 50 % of a filling agent and a sweetener
PCT/TR2012/000010 WO2012093979A1 (en) 2011-01-06 2012-01-06 Water-soluble dosage forms comprising ibandronate
EP12704937.7A EP2661270A1 (en) 2011-01-06 2012-01-06 Water-soluble dosage forms comprising ibandronate
PCT/TR2012/000006 WO2012093975A1 (en) 2011-01-06 2012-01-06 Water soluble formulations comprising ibandronate sodium with a water content less than 11 % by weight

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2011/00151A TR201100151A2 (en) 2011-01-06 2011-01-06 Ibandronate formulation.

Publications (1)

Publication Number Publication Date
TR201100151A2 true TR201100151A2 (en) 2012-07-23

Family

ID=46457629

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2011/00151A TR201100151A2 (en) 2011-01-06 2011-01-06 Ibandronate formulation.

Country Status (3)

Country Link
EP (1) EP2661270A1 (en)
TR (1) TR201100151A2 (en)
WO (1) WO2012093979A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104922060B (en) * 2015-05-23 2017-10-20 河北仁合益康药业有限公司 A kind of Ibandronate composition
CN107670103A (en) * 2017-09-15 2018-02-09 天津大学 The bone cement and preparation method that polyethylene pyrrole network alkanone is modified

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3623397A1 (en) 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh NEW DIPHOSPHONIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
ATE256456T1 (en) * 1996-05-17 2004-01-15 Merck & Co Inc BIPHOSPHONATE FORMULATION WITH EFFORTABLE EFFECT
US5853759A (en) * 1996-05-17 1998-12-29 Merck & Co.. Inc. Effervescent alendronate formulation
US20060034921A1 (en) * 2004-01-05 2006-02-16 Katdare Ashok V Effervescent bisphosphonate formulation
US20070087052A1 (en) * 2005-10-19 2007-04-19 Katdare Ashok V Effervescent bisphosphonate formulation

Also Published As

Publication number Publication date
EP2661270A1 (en) 2013-11-13
WO2012093979A1 (en) 2012-07-12

Similar Documents

Publication Publication Date Title
CY1124928T1 (en) PYRAZOLYL QUINOXALINE KINASE INHIBITORS
PH12017501306A1 (en) Inhibitors of histone demethylases
IN2014DN10670A (en)
TN2012000465A1 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
BR112015010663A8 (en) sustained release oral dosage forms, and use of ruxolitinib or a pharmaceutically acceptable salt thereof
EA202092456A2 (en) COMBINATION THERAPY INCLUDING MDM2 INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR TREATMENT OF VARIOUS TYPES OF CANCER
HN2012000023A (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITARY DISEASES
IN2014MN00948A (en)
TW201129382A (en) Antibody formulation and therapeutic regimens
MY183534A (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
EA201591363A1 (en) TIADIAZOLE ANALOGUES AND METHODS OF TREATMENT OF STATES ASSOCIATED WITH SMN DEFICIENCY
EA201691695A1 (en) THERAPEUTIC COMPOSITIONS CONTAINING RILPIVIRIN HCL AND TENOFOVIRA DYSOPROXYL FUMARATE
PH12014500386A1 (en) Combination treatment for hepatitis c
UA116999C2 (en) SELECTED HEMAGLUTIN ANTIBODY AND PHARMACEUTICAL COMPOSITION TO BE CONTAINED
MX2016002580A (en) Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases.
MX2014010537A (en) Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions.
UY33530A (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY AND INFLAMMATORY DISEASES
EA201270728A1 (en) PURINE CONNECTIONS
TR201004464A2 (en) Formulation for bone resorption.
EA201171414A1 (en) IAP FAMILY INHIBITORS
CY1116158T1 (en) Substituted 2-oxo- and 2-thiooxy-dihydroquinoline-3-carboxamides as KCNQ2 / 3 modulators
MX2013010367A (en) Compositions and methods for the therapy and diagnosis of influenza.
MX2015007945A (en) Uses and methods for the treatment of liver diseases or conditions.
MX362533B (en) Combination of somatostatin-analogs with 11beta-hydroxylase inhibitors.
TR201100151A2 (en) Ibandronate formulation.